The Q4 data highlights sustained growth in key specialty sectors, marked by notable increases in SP drug approvals and ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic ...

The top 5 biosimilar-related articles of the year highlight a significant shift in the pharmaceutical industry, with projections indicating strong uptake in biosimilars at the expense of the ...

The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs. That was certainly one of the ...

The impact of pharmaceutical companies' evergreening strategies on the adoption of trastuzumab biosimilars in the Netherlands led to significant price reductions and increased market share. The ...

This near miss is a common incident in the community practice setting given its fast pace and evolving prevalence of biosimilar usage. Biosimilars May Decrease The Cost Of Cancer Care The trajectory ...

In the first year on the market, the uptake of biosimilars for Humira (adalimumab) was low but there was lower net spending and prices on adalimumab, which was likely because of rebates from AbbVie, ...

WASHINGTON, Dec. 17, 2024 /PRNewswire/ -- Biosimilars could lower the cost of treating cancer, autoimmune disorders and other serious conditions if policies allowed patients to access the medicati ...

Personal Growth - thin line vector icon set. Pixel perfect. Editable stroke. The set contains icons: Leadership, Learning, Career, Skill, Motivation, Moving Up ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a ...

The US FDA has approved the first biosimilar version of AstraZeneca/Alexion’s Soliris therapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic ...